Fulzerasib is a small-molecule KRAS G12C inhibitor developed as a targeted anticancer agent. It is also known by the development codes IBI351 and GFH925. Fulzerasib selectively targets the KRAS G12C mutant protein and inhibits KRAS-dependent signaling pathways involved in tumor-cell growth and proliferation.
Fulzerasib is a specialized oncology pharmaceutical compound used in targeted cancer research and drug development. It has been investigated particularly for cancers containing the KRAS G12C mutation, including non-small-cell lung cancer and other solid tumors.
CAS Number: 2641747-54-6
Molecular Formula: C32H30ClFN6O4
Molecular Weight: 617.08 g/mol
Development Codes: IBI351, GFH925
Drug Class: KRAS G12C Inhibitor
Therapeutic Class: Antineoplastic / Targeted Therapy
Therapeutic Area: Oncology
The CAS number and the C32H30ClFN6O4 molecular composition are reported by ChEMBL and chemical research databases.
Fulzerasib is an irreversible inhibitor of the KRAS G12C mutant protein. It covalently interacts with the mutant KRAS protein and stabilizes KRAS in its inactive GDP-bound state. This suppresses downstream KRAS signaling, including pathways associated with ERK activation, cell proliferation and tumor growth.
Fulzerasib has been investigated as a targeted anticancer compound for tumors harboring KRAS G12C mutations. Research has included non-small-cell lung cancer and other KRAS G12C-mutated solid tumors.
KRAS mutations are important drivers of tumor development and progression. Fulzerasib is designed to selectively inhibit the G12C-mutated form of KRAS while targeting the aberrant signaling responsible for continued cancer-cell proliferation.
Fulzerasib is a synthetic small molecule containing chlorine, fluorine and multiple nitrogen- and oxygen-containing functional groups. It has a molecular formula of C32H30ClFN6O4 and molecular weight of approximately 617.08 g/mol. Research-grade material is described as a solid, with reported appearance ranging from light yellow to yellow.
Fulzerasib API quality evaluation may include identity testing by HPLC, LC-MS and spectroscopic techniques, assay determination, related substances, residual solvents, water content and elemental impurity testing. Appropriate validated analytical procedures should be used for pharmaceutical development and quality control.
Fulzerasib should be stored according to the applicable material specification and stability data. Research-grade material is commonly stored as a powder at controlled low temperature; the exact storage condition should follow the manufacturer's CoA and SDS.
Fulzerasib represents a targeted approach to oncology drug development by directly addressing the KRAS G12C mutation. Its ability to inhibit mutant KRAS signaling makes it relevant to research into molecularly targeted therapies and combination treatment strategies.
Fulzerasib is a KRAS G12C-targeted anticancer compound identified by CAS Number 2641747-54-6, with molecular formula C32H30ClFN6O4 and molecular weight 617.08 g/mol. It is also known as IBI351 and GFH925 and has been investigated in oncology, particularly for KRAS G12C-mutated solid tumors.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | Conforms by HPLC and LC-MS |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 1.0% |
| Heavy Metals | NMT 20 ppm |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |